New cancer drug
News brief.
Research Headlines
New cancer drug
By Jeanne Sabatie, Production Editor
The FDA recently approved Gleevec for the treatment of chronic myelogenous leukemia. Gleevec was 16 years in the making and doesn't come cheapcosting up to $2,400 a month, although the manufacturer offers a sliding scale on the price in proportion to patients' income levels. Scientists report that the Novartis drug also seems to work for a cancer known as GIST (gastrointestinal stromal tumor). Though both cancers are rare, researchers hope to develop similar drugsthat kill cancer cells while sparing healthy onesfor many other cancers.
Jeanne Sabatie. New cancer drug.
Business and Health
2001;6:8.
FDA Lifts Safety Restrictions on CAR T Therapies After Reviewing Real-World Data
July 2nd 2025FDA officials have determined that information regarding the risks for six CAR T-cell therapies can be communicated through product labeling, which includes a boxed warning for the risks of cytokine release syndrome and neurological toxicities.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
